enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial

​enGene Holdings Inc. (NASDAQ:ENGN) is one of the Best Up and Coming Canadian Stocks to Buy. enGene Holdings Inc. (NASDAQ:ENGN) has gained more than 31% since the company reported positive results from its Phase 2 LEGEND trial on November 11.

​Wall Street also maintains a positive outlook with analysts’ 12-month price target of $23 reflecting more than 190% upside from the current level. On November 12, David Dai from UBS reiterated a Hold rating on the stock with a $10 price target. On the same day, Judah Frommer from Morgan Stanley reiterated a Buy rating on the stock with a price target of $18.

​enGene Holdings Inc. (NASDAQ:ENGN) reported an improved complete response rate of 62% at 6 months of Detalimogene voraplasmid to treat high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Management noted that at 3 months, the complete response rate was 56% However, at 6 months, the response rate improved to 62% among 37 patients.

​The preliminary data from the trial suggest that the company remains on track for its planned Biologics License Application submission in the second half of 2026.

​enGene Holdings Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company developing non-viral genetic medicines for the delivery of therapeutics to mucosal tissues and other organs.

While we acknowledge the potential of ENGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ENGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.